文献速递肝病

肠道菌群来源的丁酸盐通过表观遗传与代谢重编程诱导髓系抑制细胞以缓解原发性胆汁性胆管炎

Gut Microbiota-Derived Butyrate Induces Epigenetic and Metabolic Reprogramming in Myeloid-Derived Suppressor Cells to Alleviate Primary Biliary Cholangitis.
PubMed 文献 · Gastroenterology · 2024-05-27

研究测量了两个独立原发性胆汁性胆管炎(PBC)队列的粪便短链脂肪酸和循环髓系抑制细胞(MDSC),并在体外用丁酸盐分化人及小鼠MDSC,结合转录组、表观遗传和代谢分析,以及2-辛炔酸-牛血清白蛋白诱导的小鼠胆管炎模型。结果发现对熊去氧胆酸应答不完全的患者丁酸盐水平降低且MDSC功能缺陷;丁酸盐通过PPARD驱动的脂肪酸β氧化(FAO)及抑制HDAC3增强PPARD和FAO基因启动子区H3K27乙酰化,促进MDSC扩增和抑制活性,从而缓解小鼠胆管炎。

要点

  • 对熊去氧胆酸应答不完全的PBC患者粪便丁酸盐水平降低且循环MDSC功能缺陷。
  • 丁酸盐以依赖PPARD驱动脂肪酸β氧化的方式诱导MDSC扩增和抑制活性。
  • 丁酸盐抑制HDAC3,增强MDSC中PPARD和FAO基因启动子区H3K27乙酰化。

核心结论

  • 丁酸盐通过协调表观遗传与代谢交互作用调控MDSC稳态,作者提出其作为治疗PBC的新型治疗策略。

研究设计与样本

  • 在2个独立PBC队列中采用靶向气相色谱-质谱法测定粪便短链脂肪酸,并用流式细胞术分析循环MDSC。
  • 体外在有丁酸盐存在下分化人及小鼠MDSC,并进行转录组、表观遗传(CUT&Tag-seq和染色质免疫沉淀-定量聚合酶链反应)及代谢(非靶向液相色谱-质谱、线粒体压力测试和同位素示踪)分析。
  • 在2-辛炔酸-牛血清白蛋白诱导的胆管炎小鼠模型中评估丁酸盐-MDSC的体内作用。

主要发现

  • 与应答充分的患者相比,对熊去氧胆酸应答不完全的PBC患者丁酸盐水平降低且MDSC功能缺陷。
  • 丁酸盐诱导MDSC扩增和抑制活性,该作用依赖PPARD驱动的脂肪酸β氧化。
  • 药物抑制或基因敲低FAO限速基因CPT1A可消除丁酸盐的效应。
  • 丁酸盐抑制HDAC3功能,导致MDSC中PPARD和FAO基因启动子区组蛋白H3第27位赖氨酸乙酰化增强。
  • 丁酸盐给药通过MDSC缓解小鼠免疫介导的胆管炎,过继转移丁酸盐处理的MDSC也显示保护效力;熊去氧胆酸无应答者的MDSC中FAO基因表达降低和线粒体生理受损,其受损的抑制功能可被丁酸盐恢复。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Gut dysbiosis and myeloid-derived suppressor cells (MDSCs) are implicated in primary biliary cholangitis (PBC) pathogenesis. However, it remains unknown whether gut microbiota or their metabolites can modulate MDSCs homeostasis to rectify immune dysregulation in PBC. METHODS: We measured fecal short-chain fatty acids levels using targeted gas chromatography-mass spectrometry and analyzed circulating MDSCs using flow cytometry in 2 independent PBC cohorts. Human and murine MDSCs were differentiated in vitro in the presence of butyrate, followed by transcriptomic, epigenetic (CUT&Tag-seq and chromatin immunoprecipitation-quantitative polymerase chain reaction), and metabolic (untargeted liquid chromatography-mass spectrometry, mitochondrial stress test, and isotope tracing) analyses. The in vivo role of butyrate-MDSCs was evaluated in a 2-octynoic acid-bovine serum albumin-induced cholangitis murine model. RESULTS: Decreased butyrate levels and defective MDSC function were found in patients with incomplete response to ursodeoxycholic acid, compared with those with adequate response. Butyrate induced expansion and suppressive activity of MDSCs in a manner dependent on PPARD-driven fatty acid β-oxidation (FAO). Pharmaceutical inhibition or genetic knockdown of the FAO rate-limiting gene CPT1A abolished the effect of butyrate. Furthermore, butyrate inhibited HDAC3 function, leading to enhanced acetylation of lysine 27 on histone H3 at promoter regions of PPARD and FAO genes in MDSCs. Therapeutically, butyrate administration alleviated immune-mediated cholangitis in mice via MDSCs, and adoptive transfer of butyrate-treated MDSCs also displayed protective efficacy. Importantly, reduced expression of FAO genes and impaired mitochondrial physiology were detected in MDSCs from ursodeoxycholic acid nonresponders, and their impaired suppressive function was restored by butyrate. CONCLUSIONS: We identify a critical role for butyrate in modulation of MDSC homeostasis by orchestrating epigenetic and metabolic crosstalk, proposing a novel therapeutic strategy for treating PBC.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Wang R, Li B, Huang B, et al. Gut Microbiota-Derived Butyrate Induces Epigenetic and Metabolic Reprogramming in Myeloid-Derived Suppressor Cells to Alleviate Primary Biliary Cholangitis. Gastroenterology. 2024. PMID: 38810839. doi:10.1053/j.gastro.2024.05.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。